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Engineered cytokines are gaining importance for cancer therapy but those products are often 
limited by toxicity, especially at early time points after intravenous administration. 4-1BB is a 
member of the tumor necrosis factor receptor superfamily, which has been considered as a target 
for therapeutic strategies with agonistic antibodies or using its cognate cytokine ligand, 4-1BBL. 
Here we describe the engineering of an antibody fusion protein (termed F8-4-1BBL), which does 
not exhibit cytokine activity in solution but regains biological activity upon antigen binding. F8-4-
1BBL bound specifically to its cognate antigen, the alternatively-spliced EDA domain of 
fibronectin, and selectively localized to tumors in vivo, as evidenced by quantitative biodistribution 
experiments. The product promoted a potent anti-tumor activity in various mouse models of 
cancer, without apparent toxicity at the doses used. F8-4-1BBL represents a prototype for 
antibody-cytokine fusion proteins, which conditionally display “activity-on-demand” properties at 







Antibody-cytokine fusion proteins have been successfully applied for the treatment of preclinical 
models of cancer and yielded promising results in early clinical trials. The antibody moiety 
redirects the immunostimulatory payload to the tumor in order to boost the anti-tumor immune 
response. However, especially at early timepoints after administration, the relatively high 
concentration of the antibody-cytokine conjugate in blood can lead to severe side effects due to 
peripheral activation of cytokine receptors. Therefore, protein engineering approaches are 
necessary in order to develop antibody-cytokine conjugates that selectively regain their 
immunostimulatory activity upon antigen binding in the tumor. In this work, we have developed an 
antibody-cytokine conjugate that meets these criteria and which showed antitumor activity in 











Cytokines are immunomodulatory proteins, which have been considered for pharmaceutical 
applications for the treatment of cancer patients(1-3) and other types of disease(2). There is a 
growing interest in the use of engineered cytokine products as anti-cancer drugs, capable of 
boosting the action of T cells and natural killer (NK) cells against tumors(3, 4), alone or in 
combination with immune check-point inhibitors(3, 5-7).   
Recombinant cytokine products on the market include IL2 (Proleukin)(8, 9), IL11 
(Neumega)(10, 11), TNF (Beromun)(12), IFN (Roferon A, Intron A)(13, 14), IFN 
(Avonex, Rebif, Betaseron)(15, 16), IFN (Actimmune)(17), G-CSF (Neupogen)(18), 
GM-CSF (Leukine)(19, 20). The recommended dose is typically very low (often at less than one 
milligram per day)(21-23), as cytokines may exert biological activity in the subnanomolar 
concentration range(24). In order to develop cytokine products with improved therapeutic index, 
various strategies have been proposed. Protein PEGylation or Fc fusions may lead to prolonged 
circulation time in the bloodstream, allowing the administration of low doses of active payload(25, 
26). In some implementation, cleavable PEG polymers may be considered, yielding prodrugs 
which regain activity at later time points(27). Alternatively, tumor-homing antibody fusions have 
been developed, since the preferential concentration of cytokine payloads at the tumor site has 
been shown in preclinical models to potentiate therapeutic activity, helping spare normal 
tissues(28-34). Various antibody-cytokine fusions are currently being investigated in clinical trials 
for the treatment of cancer and of chronic inflammatory conditions [for reviews, see(2, 33, 35-37)]. 
Antibody-cytokine fusions display biological activity immediately after injection to patients, which 
may lead to unwanted toxicity and prevent escalation to therapeutically active dose regimens(9, 
22, 38). In the case of pro-inflammatory payloads (e.g., interleukin-2, interleukin-12, tumor 
necrosis alpha), common side effects include hypotension, nausea and vomiting, as well as flu-
like symptoms(24, 39-42). These side-effects typically disappear when the cytokine concentration 
drops below a critical threshold, thus providing a rationale for slow-infusion administration 
procedures(43). It would be highly desirable to generate antibody-cytokine fusion proteins with 
excellent tumor targeting properties and with “activity-on-demand” (i.e., with a biological activity 






Here, we describe a novel fusion protein, consisting of the F8 antibody (specific to the 
alternatively-spliced EDA domain of fibronectin(44, 45)) and of murine 4-1BBL, which did not 
exhibit cytokine activity in solution but could regain potent biological activity upon antigen binding. 
The antigen is conserved from mouse to man(46), is virtually undetectable in normal adult tissues 
(exception made for placenta, endometrium and some vessels in the ovaries), but is expressed in 
the majority of human malignancies(44, 45, 47, 48). 4-1BBL is a member of the tumor necrosis 
factor superfamily(49). It is expressed on antigen-presenting cells(50, 51) and binds to its 
receptor 4-1BB which is upregulated on activated cytotoxic T cells(52), activated dendritic 
cells(52), activated NK and NKT cells(53) and on regulatory T cells(54). Signaling through 4-1BB 
on cytotoxic T cells protects them from activation-induced cell death and skews the cell towards a 
more memory-like phenotype(55, 56). 
We engineered nine formats of the F8-4-1BBL fusion protein and one of them exhibited a 
superior performance in quantitative biodistribution studies and conditional gain of cytokine 
activity upon antigen binding. The antigen-dependent reconstitution of the biological activity of the 
immunostimulatory payload represents an example for an antibody fusion protein with “activity on 
demand”. The fusion protein was potently active against different types of cancer, without 
apparent toxicity at the doses used. F8-4-1BBL may represent a prototype for next-generation 
antibody-cytokine fusions with “activity-on-demand”. The EDA domain of fibronectin is a 
particularly attractive antigen for cancer therapy, in view of its high selectivity, stability and 








Human 4-1BBL is a homotrimeric protein [Figure 1a](57), while its murine counterpart forms 
stable homodimers(58, 59). Stable trimeric structures can be engineered by connecting 4-1BBL 
monomeric domains with suitable polypeptide linkers(60). Recombinant antibodies can be 
expressed as full IgG or as fragments, forming single-chain Fv (scFv)(61, 62)  or diabody(63)  
structures [Figure 1b and Supplementary Table S1](2, 64, 65). Nine different fusion proteins 
containing F8 antibody and murine 4-1BBL moieties were expressed in mammalian cells, in order 
to identify products with promising features for subsequent in vivo investigations. Mutational 
scans had revealed that the disulfide bond linking two 4-1BBL monomers is crucial for protein 
stability [Supplementary Figure S1]. The observation that the TNF homology domain (THD) 
within 4-1BBL was sufficient for full in vitro activity [Supplementary Figure S2] guided the design 
of the modules to be included in the fusion proteins. Six out of nine products exhibited favorable 
size exclusion and SDS-PAGE profiles [Figure 1c and Supplementary Figure S3]. We selected 
formats 2, 3, 5, 7 and 8 for further investigations, since those proteins gave the best yields and 
did not show signs of aggregation even after repeated freeze-thaw cycles.  
Figure 2 presents a comparative analysis of in vitro properties of F8-4-1BBL in various formats. 
The 4-1BBL and F8 moieties were able to recognize the cognate targets in the 2, 3, 5, 7 and 8 
formats. Indeed, all proteins bound with high affinity to murine CTLL-2 cells, which are strongly 
positive for murine 4-1BB (i.e., the 4-1BBL receptor) [Figure 2a] and to recombinant EDA domain 
of fibronectin [Figure 2b]. A functional assay with an NF-B reporter cell line(66) revealed that all 
fusion proteins preferentially activated downstream signaling events in the presence of the 
cognate EDA fibronectin antigen, immobilized on a solid support and thus mimicking the tumor 
environment [Figure 2c]. Formats 5 [consisting of two disulfide-linked 4-1BBL monomeric units 
fused to scFv(F8)] and 8 [in which monomeric units of 4-1BBL were fused at the C-terminal ends 
of the heavy chains of IgG(F8)] exhibited the best discrimination between low biological activity in 
solution and high cytokine activity in the presence of antigen. For this reason, formats 5 and 8 
were selected for an in vivo characterization of their tumor targeting properties. Format 2 was 
also included in the comparison, since diabody-based antibody cytokine fusion proteins have 
previously been used for clinical development programs(2, 64). 
Protein preparations were radioiodinated and injected into immunocompetent 129/Sv mice, 
bearing subcutaneously-grafted murine F9 teratocarcinomas, which express EDA fibronectin 
around tumor blood vessels(44). Mice were sacrificed 24 hours after intravenous administration 
and biodistribution results were expressed as percent of injected dose per gram of tissue [%ID/g] 





(1.0% ID/g) and poor selectivity. Format 8 showed, as expected, a longer circulatory half-life, as 
evidenced by the high %ID/g in blood after 24 h, but the tumor uptake and selectivity were not 
significantly higher compared to KSF-4-1BBL (a fusion protein based on the KSF antibody, 
specific to hen egg lysozyme and serving as negative control(67)). By contrast, format 5 exhibited 
a preferential accumulation in the tumor (2.8 % ID/g) and a good tumor-to-normal organ 
selectivity. EDA targeting was essential for tumor homing, as revealed by the comparison of the 
biodistribution results with the negative control KSF-4-1BBL fusion protein [Figure 3a and 
Supplementary Figure S4]. In order to confirm selective tumor uptake with a different 
methodology, format 5 was injected into tumor-bearing mice. An ex vivo immunofluorescence 
analysis revealed a preferential accumulation of format 5 around tumor blood vessels, while no 
staining was detectable in normal organs or when the KSF fusion protein was used [Figure 3b 
and Supplementary Figure S5]. In line with previous reports on this matter(44, 45, 47, 48), the 
EDA-domain of fibronectin is an ideal target for pharmacodelivery applications in mouse and in 
man, as the antigen is undetectable in normal adult tissues, but is strongly expressed in the 
stroma and around the blood vessels in many different tumor types [Supplementary Figure S6]. 
Therapy studies were performed using format 5 of F8-4-1-BBL, both in a preventive setting 
starting at a tumor volume of 40 mm3 and in a therapeutic setting starting at a tumor volume of 80 
– 100 mm3. In a preventive setting in WEHI-164 fibrosarcoma, three out of five mice rejected the 
tumor using F8-4-1-BBL as single agent, while four out of five mice showed a complete response 
when treated with PD-1 blockade, alone or in combination with F8-4-1-BBL [Figure 4a]. The 
cured mice rejected subsequent challenges with WEHI-164 fibrosarcoma cells. In some cured 
mice, a challenge with CT26 colon carcinoma cells was also rejected, similar to what we had 
previously reported for other F8-based immunocytokine therapeutics (68, 69)[Supplementary 
Figure S7]. When the therapy was repeated in mice bearing larger WEHI-164 fibrosarcoma 
tumors, a significant [p = 0.0427, regular two-way ANOVA, Tukey’s multiple comparison test, day 
13] tumor growth retardation was observed in mice treated with F8-4-1BBL [Figure 4b]. There 
was no difference in tumor growth between mice receiving injections of saline and the KSF fusion 
proteins, underlining the importance of the antigen-dependent activation of 4-1BBL [Figure 4b]. 
Similar experiments performed in immunocompetent mice bearing CT26 tumors showed a tumor 
regression in 4/5 mice treated with F8-4-1BBL. One mouse was cured, while tumors eventually 
regrew in the other mice. Therapy was potent also when F8-4-1BBL was combined with PD-1 
blockade [Figure 4c]. All treatments in all experiments were well tolerated, as indicated by the 
absence of body weight loss [Figure 4]. When MC38 colon carcinoma-bearing mice were treated 
with F8-4-1BBL or PD-1 blockade as single agents, a moderate tumor growth retardation 





Tukey’s multiple comparison test, day 13]. By contrast, the combination treatment was potently 
active and led to durable complete remissions in 2/6 mice [Figure 4 d].  
To further investigate the therapeutic activity of F8-4-1BBL, alone or in combination with PD-1 
blockade, we studied an orthotopic model of glioblastoma in immunocompetent mice. Treatment 
was started 5 days after intracerebral implantation of GL-261 tumor cells. Mice were imaged at 
day 12 by magnetic resonance imaging (MRI) and were monitored in terms of body weight and 
behavior. Mice were sacrificed when they developed neurologic symptoms. In keeping with 
previous reports, none of the mice from the saline treatment group survived more than 20 days. 
By contrast, F8-4-1BBL exhibited a potent anticancer activity, which was potentiated by PD-1 
blockade. Eighty percent of the mice in the combination treatment group were rendered tumor-
free, as evidenced both by MRI analysis and by survival data [Figure 4e]. 
In order to analyze the tumor infiltrating leukocytes, mice were sacrificed 48 h after the second 
cycle of injections. Tumors and tumor-draining lymph nodes were excised, homogenized and 
stained for analysis by flow cytometry. CT26 tumors were found to be highly infiltrated by 
lymphocytes, in keeping with previous reports(70-72), while WEHI-164 lesions were rather 
immunologically “cold” [Figure 5a]. The proportion of CD8+ T cells, specific to AH1 (a retroviral 
antigen, which plays a dominant role for the rejection of tumors implanted in BALB/c mice (69, 
73)) was higher in CT26 tumors [Figure 5a]. Treatment with F8-4-1BBL led to a significant 
increase in intratumoral CD3+ T cell density in both models, but the proportion of CD4+ or CD8+ 
T cells did not vary substantially. No difference was observed in terms of regulatory T cell (Treg) 
density [Figure 5a]. In keeping with what previously reported for other studies(74), the proportion 
of AH1-specific CD8+ T cells did not vary substantially as a result of pharmacological treatment 
[Figure 5a]. Treatment with F8-4-1BBL led to a decrease in CD3+ and CD4+ T cells in the tumor-
draining lymph nodes with a concomitant increase of antigen-presenting cells in CT26 tumor-
bearing mice (but not in WEHI-164) [Figure 5b]. An increase in the proportion of effector T cells 
(CD44+CD62L-) was observed among the AH1-specific CD8+ T cells in the tumor-draining lymph 
nodes [Figure 5c]. Virtually all tumor-infiltrating CD8+ T cells were positive for the exhaustion 
markers PD-1 and CD39 [Figure 5c](75, 76). The gating strategy used in the study can be found 
in Supplementary Figure 7. Collectively, the markers used in this study did not detect a 
phenotypic change in tumor-infiltrating T cells, but an increase in effector T cells was observed for 










We have described the development of an antibody-cytokine fusion protein targeted to the tumor 
neovasculature, featuring an engineered murine homodimeric 4-1BBL moiety as 
immunostimulatory payload. Some formats were completely inactive in solution while others 
retained a low biological activity in the absence of antigen. The low constitutive biological activity 
of the formats featuring two single-chain trimeric ligands could be due to a residual receptor 
clustering triggered by hexameric 4-1BBL. The size exclusion profile of Format 7 revealed the 
presence of a minor fraction of aggregated protein, which could potentially trigger some 
downstream signaling. However, since it was not possible to remove the aggregated fraction, this 
hypothesis could not be experimentally proven. Subtle variations in the molecular format were 
observed to not only lead to different performance in vitro but also affected the biodistribution 
properties in vivo. Both preferential localization in the tumor and antigen-dependent gain in 
activity are prerequisites for restricting the activity of the fusion protein to the site of disease. The 
selected format 5 was inactive in solution but regained activity upon clustering on the antigen. 
Favorable tumor-targeting results and potent tumor growth inhibition were observed in vivo, 
making F8-4-1BBL a promising prototype of for the development of next-generation 
immunocytokines with antigen-dependent activation properties.  
4-1BB, the receptor for 4-1BBL has been recognized as important target for the immunotherapy 
of cancer, as this member of the TNF receptor superfamily delivers costimulatory signals to 
activated cytotoxic T cells(77). The first 4-1BB agonistic antibody, urelumab, showed promising 
anti-cancer activity in preclinical models, but unfortunately revealed substantial hepatotoxicity in 
clinical trials(78). The hepatic toxicity was mainly due to the activation of liver Kupffer cells and 
monocytes, leading to a massive infiltration by T cells(78, 79). Efforts are being made to develop 
4-1BB agonists with more favorable toxicity profiles that retain potent costimulatory capacities(80-
82). In addition to the optimization of anti-4-1BB immunoglobulins(80, 81), various formats of 
targeted 4-1BB agonists are being investigated. Bispecific antibodies capable of simultaneous 
recognition of 4-1BB and of tumor-associated antigens (e.g., EGFR or CEA) have been 
developed and tested in preclinical models of cancer, with encouraging results (82, 83). Novel 
formats of targeted 4-1BB agonists have recently been considered for clinical development. A 
FAP-targeted immunocytokine with trimeric single-chain 4-1BBL has recently started phase I 
clinical testing in cancer patients (84). A fusion protein of trastuzumab with a 4-1BB-specific 
anticalin™ has been described(85), which had shown antigen-dependent modulation of 4-1BB 





The search for antibody-cytokine products with “activity-on-demand” has been recognized as an 
important research goal, in order to generate products with improved activity and safety 
profiles(86, 87). One possible strategy features the use of cytokine-binding polypeptides, acting 
as proteolytically-cleavable inhibitory moieties(88). Fusing cytokines at the C-terminal end of the 
IgG light chain may restrict conformational changes in the hinge region and slightly modulate 
cytokine activity upon antibody binding to the cognate antigen(87). The attenuation of cytokine 
potency by targeted mutagenesis has been considered as a strategy to increase the dose of 
antibody-cytokine fusion proteins(89) or to conditionally activate tumor cells which express both a 
tumor-associated antigen and a cytokine receptor (e.g., IFN receptor) on their surface(90, 91). 
In addition, the targeted reconstitution of antibodies fused with “split-cytokine” moieties (i.e., 
subunits of heterodimeric cytokines that can reassemble at the tumor site) has been reported. 
Until now, the performance of that approach has been limited by the fact that the cytokine 
subunits used in the study (e.g., the p35 chain of IL12) retained biological activity(92). 
Most ligands of the TNF superfamily including human 4-1BBL form homotrimers instead of 
homodimers as is the case for murine 4-1BBL(93). However, the activation of receptor of the TNF 
superfamily requires higher-order multimerization. The approach described in this article may be 
generally applicable to members of the TNF superfamily (60), if we were able to generate stable 
homodimers as payloads for antibody fusion. Alternative approaches may involve bispecific 
antibodies(94, 95), the modular use of small protein domains(85, 96) or of chemically-modified 
bicyclic peptides(97). Members of the TNF receptor superfamily are particularly suited for 
cooperative activation strategies in view of their homotrimeric structure and clustering-driven 
activation properties(98-100). The development of immunotherapeutics with “activity-on-demand” 
for monomeric cytokines may be more challenging, as one cannot rely on protein assembly for 







Materials and Methods 
 
Cell lines 
The murine cytotoxic T cell line CTLL-2 (ATCC® TIB-214), the murine F9 teratocarcinoma cell 
line (ATCC® CRL-1720), the murine WEHI-164 fibrosarcoma cell line (ATCC® CRL-1751) and 
the murine CT26 colon carcinoma cell line (ATCC® CRL-2638) were obtained from ATCC. The 
MC38 colon carcinoma cell line was a kind gift from Prof. Onur Boyman (Department of 
Immunology, University Hospital Zurich, Zurich, Switzerland). The cells were expanded and 
stored as cryopreserved aliquots in liquid nitrogen. The CTLL-2 cells were grown in RPMI 1640 
(Gibco, #21875034) supplemented with 10% FBS (Gibco, #10270106), 1 X antibiotic-
antimycoticum (Gibco, #15240062), 2 mM ultraglutamine (Lonza, #BE17-605E/U1), 25 mM 
HEPES (Gibco, #15630080), 50 M -mercaptoethanol (Sigma Aldrich) and 60 U/mL human IL-2 
(Proleukin, Roche Diagnostics). The F9 teratocarcinoma cells were grown in DMEM (Gibco, high 
glucose, pyruvate, #41966-029) supplemented with 10% FBS (Gibco, #10270106) and 1 X 
antibiotic-antimycoticum (Gibco, #15240062) in flasks coated with 0.1% gelatin (Type B from 
Bovine Skin, Sigma Aldrich, #G1393). The WEHI-164 fibrosarcoma and the CT26 colon 
carcinoma were grown in RPMI 1640 (Gibco, #21875034) supplemented with 10% FBS (Gibco, 
#10270106) and 1 X antibiotic-antimycoticum (Gibco, #15240062). The MC38 colon carcinoma 
cells were grown in Advanced DMEM (Gibco, #12491915) supplemented with 10% FBS (Gibco, 
#10270106), 1 X antibiotic-antimycoticum (Gibco, #15240062) and 2 mM ultraglutamine (Lonza, 
#BE17-605E/U1). GL-261 cells were obtained from the National Cancer Institute (Frederick, 
Maryland, USA) and cultured as previously described(101, 102). The cells were passaged at the 
recommended ratios and never kept in culture for more than one month.  
Mice 
Eight weeks old female C57BL/6, Balb/c and 129/Sv mice were obtained from Janvier. After at 
least one week of acclimatization, 107 F9 cells, 2.5 x 106 WEHI-164 cells, 4 x 106 CT26 or 106 
MC38 cells were subcutaneously implanted into the right flank. The tumor size was monitored 
daily by caliper measurements and the volume was calculated using the formula [length x width x 
width x 0.5]. For mouse studies mouse models of glioblastoma, eight weeks old female C57BL/6 
mice were purchased from Charles River Laboratories (Sulzfeld, Germany). Intracranial tumor 
cell implantation has been previously described(101). The animal experiments were carried out 
under the project license ZH04/2018 (subcutaneous tumor models) and ZH73/2018 
(glioblastoma) granted by the Veterinäramt des Kantons Zürich, Switzerland, in compliance with 






A soluble single-chain trimer of murine 4-1BBL was designed by linking the TNF homology 
domain (amino acids 139 – 309) with a single glycine as a linker. The genetic sequence was 
ordered from Eurofins Genomics. The sequence was then introduced into a vector encoding the 
F8 in a diabody format by Gibson Isothermal Assembly. To clone the single-chain variable 
Fragment (scFv) linked to the 4-1BBL monomer, the genetic sequence encoding the diabody was 
replaced by the sequence encoding the scFv and two domains of 4-1BBL were removed by PCR 
followed by blunt-end ligation. Additional base pairs of 4-1BBL were added to the 4-1BBL 
sequence by PCR followed by blunt-end ligation. The IgG fusion proteins were cloned by fusing 
the 4-1BBL sequence to the sequence of the antibody in the IgG format by PCR before 
introducing it into an appropriate vector by restriction cloning. The protein sequences are 
provided in [Supplementary Table S1]. 
Protein production 
Proteins were produced by transient transfection of CHO-S cells and purified by protein A affinity 
chromatography as described previously (68, 103, 104). Quality control of the purified products 
included SDS-PAGE and size exclusion chromatography using an Äkta Pure FPLC system (GE 
Healthcare) with a Superdex S200 10/300 increase column at a flow rate of 0.75 mL/min (GE 
Healthcare) [Figure 1 and Supplementary Figure S1]. 
Binding measurements by Surface Plasmon Resonance 
To evaluate the binding kinetics of the F8 antibody fragment to EDA, a CM5 sensor chip (GE 
Healthcare) was coated with approximately 500 resonance units of an EDA-containing 
recombinant fragment of fibronectin. The measurements were carried out with a Biacore S200 
(GE Healthcare). The contact time was set to 3 min at a flow rate of 20 L/min followed by a 
dissociation for 10 min and a regeneration of the chip using 10 mM HCl.  
Binding measurements by Flow Cytometry 
In order to measure the binding of the 4-1BBL moiety to cells expressing 4-1BB, CTLL-2 cells 
were incubated with varying concentrations of the fusion proteins for 1 h. The bound protein was 
detected by addition of an excess of AlexaFluor488-labelled protein A (Thermofisher, #P11047) 
and subsequent measurement of the fluorescence using a Cytoflex Flow Cytometer. The mean 
fluorescence was normalized and the resulting binding curve was fitted using the the [Agonist] vs. 






NF-B response assay 
The development of the CTLL-2 reporter cell line is described elsewhere(66). CTLL-2_NF-B 
reporter cells were starved by washing the cells twice with prewarmed HBSS (Gibco, #14175095) 
followed by growth in the absence of IL-2 for 6 - 9 h in RPMI 1640 (Gibco, # 21875034) medium 
supplemented with 10% FBS (Gibco, #10270106), 1 X antibiotic-antimycoticum (Gibco, # 
15240062), 2 mM Ultraglutamine (Lonza, # BE17-605E/U1), 25 mM HEPES (Gibco, # 15630080) 
and 50 M -mercaptoethanol (Sigma Aldrich) in order to reduce the background signal. To coat 
the wells with antigen, 100 L 100 nM 11-A-12 fibronectin in phosphate buffered saline (PBS) 
was added to each well and the plate was incubated at 37°C for 90 min. Cells were seeded in 96-
well plates (50,000 cells/well) and growth medium containing varying concentrations of the 
antibody-cytokine conjugate was added. The cells were incubated at 37°C, 5% CO2 for several 
hours. To assess luciferase production, 20 L of the supernatant was transferred to an opaque 
96-well plate (PerkinElmer, Optiplate-96, white, #6005290) and 80 L 1 g/mL Coelenterazine 
(Carl Roth AG, #4094.3) in phosphate buffered saline (PBS) was added. Luminescence at 595 
nm was measured immediately. The relative luminescence was calculated by dividing the 
obtained results by the results obtained when no inducer was added. The data was fitted using 
the [Agonist] vs. response (three parameters) fit of the GraphPad Prism 7.0 a software to 
estimate the EC50. 
Quantitative biodistribution studies 
Quantitative biodistribution experiments were carried out as described previously(44). Briefly, 8 
weeks old female 129/Sv mice were injected subcutaneously in the right flank with 107 F9 
teratocarcinoma cells. The tumor size was measured daily with a caliper and the volume was 
calculated using the formula [volume = length x width x width x 0.5]. When the tumors reached a 
volume of 100 – 300 mm3, 10 g of radioiodinated protein was injected into the lateral tail vein. 
The mice were sacrificed 24 h after the injection and the organs were excised and weighed. The 
radioactivity of the different organs was measured (Packard Cobra II Gamma Counter) and 
expressed as percentage of injected dose per gram of tissue (%ID/g  SD, n = 3). 
Ex vivo detection of fluorescently labelled immunocytokines 
For fluorescent labelling, the proteins were resuspended in a 0.1 M sodium carbonate buffer at 
pH 9.1 and an excess of Fluorescein Isothiocyanate (FITC) was added. The reaction was carried 
out overnight at 4°C. The labelled proteins were separated from unconjugated FITC by PD-10. 
Approximately 100 g of fluorescently-labelled protein was injected into the lateral tail-vein of 





and embedded in NEG-50 cryoembedding medium (ThermoFisher, Richard-Allan-Scientific, 
#6502) prior to freezing. For staining, 8 µm cryosections were fixed in acetone and incubated with 
goat-anti-mouse CD31 (R&D system, #AF3628, 1:200) and rabbit-anti-FITC (Biorad, #4510-7804) 
followed by donkey-anti-goat-AF594 (Invitrogen, #A11058) and donkey-anti-rabbit-AF488 
(Invitrogen, #A21206). Images were acquired using a Zeiss Axioscope 2 mot plus with an 
Axiocam 503 camera at a 200 X magnification in the RGB mode. The images were processed 
using the software ImageJ v1.52k setting the thresholds for the red channel to 14-80 and the 
green channel to 15 - 100.  
Immunofluorescence on tissue microarray 
Immunofluorescence was performed onto Frozen Tumor and Normal Tissue Array (Biochain, 
#T6235700). The array was fixed by ice-cold aceton for 5 minutes. After fixation, sections were let 
dry at room temperature for 10 minutes and then blocked for 45 min with 20% fetal bovine serum 
in PBS. FITC labeled IgG(F8) was added at 5 g/ml in 2% BSA/PBS solution for 1h at room 
temperature. The tissue array was then washed twice with PBS and secondary rabbit anti-FITC 
antibody (Biorad, #4510-7804) was added to a final 1:1000 dilution in 2% BSA/PBS at room 
temperature for 1h. After washing the array twice with PBS, Goat Anti-Rabbit Alexa-488 
(ThermoFisher, #A11032) was added to a final 1:500 dilution in 2% BSA/PBS. Dapi was used to 
counterstain nuclei. Slides were analyzed with Axioskop2 plus microscope (Zeiss). 
Therapy studies in subcutaneous tumor models 
After the subcutaneous implantation of the tumor cells into the right flank of 8 weeks old female 
mice, the tumor size was monitored by caliper measurements on a daily basis [volume = length x 
width x width x 0.5]. In the preventive setting, the therapy was started when the tumor reached a 
volume of 40 mm3 and for the therapeutic setting, the therapy was started when the tumors 
reached a volume of 75 – 100 mm3. The mice were grouped in order to obtain groups of similar 
average tumor size (n = 5-6). The mice either received 100 L Saline (PBS, Gibco, #1010023), 
500 g F8(scFv)-4-1BBL, 200 g PD-1 (BioXCell, clone 29F.1A12) or a combination of the 
checkpoint inhibitor and the immunocytokine. For the combination treatment, the checkpoint 
inhibitor was administered one day prior to the immunocytokine. The therapeutic agents were 
administrated every second day in a total of three cycles intravenously into the lateral tail vein. 
The animals were sacrificed if the tumor diameter exceeded 15 mm or when the tumor started to 
ulcerate. Some cured mice were rechallenged by the subcutaneous injection of WEHI 164 or 
CT26 tumor cells after being tumor-free for at least 4 weeks. Statistical evaluations were done 
using a standard two-way ANOVA followed by the Tukey’s multiple comparison test with 





Magnetic resonance imaging and glioblastoma studies 
Coronal T2-weighted MRI images at day 12 after tumor implantation were acquired using 
Paravision 6.0 (Bruker BioSpin) on a 4.7 T small animal magnetic resonance imager 
(Pharmascan; Bruker Biospin, Ettlingen, Germany). Mean ± SD of the tumor perimeter in mm at 
the maximum circumference were determined using the Medical Image Processing, Analysis, and 
Visualization (MIPAV) software (https://mipav.cit.nih.gov/). Mice were sacrificed when developing 
neurologic symptoms. Kaplan Meier survival analysis was performed to assess survival 
differences among the treatment groups and p values were calculated with Gehan-Breslow-
Wilcoxon test using GraphPad Prism v7.0 a. Significance was tested at *p < 0.05 and **p < 0.01. 
Analysis of tumor-infiltrating lymphocytes by flow cytometry 
The mice were sacrificed 48 h after the second therapy cycle. The tumor-draining lymph nodes as 
well as the tumor were excised. A single-cell suspension of the tumor was obtained by digesting it 
in RPMI 1640 supplemented with 1 mg/mL collagenase II and 100 μg/mL DNase I for 30 min at 
37°C. After the digestion, the suspension was passed through a 70 m cell strainer. If necessary, 
the red blood cells were removed using a red blood cell lysis buffer (Roche). The lymph nodes 
were smashed on a 70 m cell strainer and washed with PBS. For cell surface staining, cells 
were incubated with a mix of suitable antibodies: CD3-APC/Cy7 (Biolegend, #100222), CD4-
APC (Biolegend, #100412), CD8-FITC (Biolegend, #100706), NK1.1-PE (Biolegend, 
#108708), CD62L-BV421 (Biolegend, #104436), CD44-APC/Cy7 (Biolegend, #103028), 
MHCII(IA/IE)-BV421 (Biolegend, #107631), PD-1-BV421 (Biolegend, #109121) and CD39-
APC (Biolegend, #143809). After staining of the cell surface markers, the cells were stained with 
7-AAD (Biolegend) for live/dead discrimination. For intracellular staining, the cells were first 
stained with Zombie Red (SigmaAldrich) and then the cell surface stain was performed. The cells 
were fixed and permeabilized using the eBioscienceTM FoxP3/Transcription Factor Staining Buffer 
Set (Thermofisher, #00-5523-00) according to the manufacturer’s instructions. The fluorescence 
was measured using a Cytoflex Flow Cytometer and the data was evaluated using the FlowJo 
software. The gating strategy is depicted in [Supplementary Figure S8]. Statistical evaluations 
were done using a regular two-way ANOVA followed by a Tukey’s multiple comparison test or a 
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Figures and Tables 
 
Figure 1. The nine F8-4-1BBL fusion proteins that were designed and tested in this study (a) 
schematic depiction of an antibody in the IgG format and of the human 4-1BBL. The human 4-
1BBL is a transmembrane protein which forms a non-covalent homotrimer(57) (b) the fusion 
proteins featuring murine 4-1BBL are schematically depicted and size exclusion chromatograms 






Figure 2. In vitro characterization of five F8-4-1BBL formats (a) binding to 4-1BB was measured 
by flow cytometry with the murine cytotoxic T cell line CTLL-2 which expresses 4-1BB (b) binding 
of the F8 moiety to the EDA-positive ectodomain of fibronectin was measured by surface plasmon 
resonance on chips coated with recombinant EDA (c) biological activity was tested using an NF-
B reporter cell line that secretes luciferase upon activation of the NF-B pathway by signaling 
through 4-1BB. The assay was performed both with and without EDA immobilized on solid 
support (n = 3). Curve fitting was done using the [agonist] vs response (three parameters) fit of 






Figure 3. In vivo biodistribution studies of three F8-4-1BBL formats (a) The mice were sacrificed 
24 h after the injection of the radioiodinated proteins and the radioactivity of excised organs 
was measured and expressed as percent injected dose per gram of tissue (%ID/g  SD, n = 3). 
The KSF antibody targeting hen egg lysozyme was used as untargeted control(67). (b) The mice 
were sacrificed 24 h after the injection of FITC-labelled F8-4-1-BBL or KSF-4-1-BBL in format 5. 
The proteins were detected ex vivo on cryosections (green: FITC, red: CD31). (c) The 
expression of EDA was assessed on human tissue microarrays using FITC-labelled F8 in the IgG 








Figure 4. Therapy studies with F8-4-1BBL in format 5 (a) The preventive therapy in WEHI-164 
fibrosarcoma-bearing mice was started on day 5 when the tumors reached a volume of 40 mm3. 
The tumor sizes are shown as mean + SD (n = 5). The body weight data is represented as mean 
body weight change  SD for each group. (b) The therapy in WEHI-164 fibrosarcoma-bearing 
mice was started on day 7 when the tumor volume was > 80mm3. The tumor sizes are shown as 
mean + SD (n = 5). The statistical results of a regular two-way ANOVA followed by a Tukey’s 
multiple comparison test using GraphPad Prism v8.4.1 on day 13 are shown (ns: not significant, * 
p = 0.0427).  The body weight data is represented as mean body weight change  SD for each 
group. (c) In CT26-colon carcinoma-bearing mice the therapy was started on day 7 when the 
tumor volume exceeded 80 mm3. The tumor sizes are shown as mean + SD (n = 5). The result of 
a regular two-way ANOVA followed by a Tukey’s multiple comparison test using GraphPad Prism 
v8.4.1 revealed that as of day 13 the tumor size of the mice treated with PD-1 blockade was 
significantly smaller than the size of the tumors treated with saline (*** p = 0.0004). (d) In MC-38 
colon carcinoma-bearing mice the therapy was started on day 7 when the tumor volume 
exceeded 75 mm3. The tumor sizes are shown as mean + SD (n = 5 - 6). The result of a regular 
two-way ANOVA followed by a Tukey’s multiple comparison test using GraphPad Prism v8.4.1 is 
shown for day 12 (*** p < 0.001). The body weight data is represented as mean body weight 
change  SD for each group. (e) GL-261 were implanted orthotopically in C57BL/6 mice. 
Subsequently, mice were treated intravenously with saline, F8-4-1BBL, PD-1 or the combination 
starting on day 5. Tumor size was assessed at day 12 after tumor implantation. MRI of five mice 
per group are shown on the left with tumors outlined in red and the quantification of tumor 
perimeters in 5 mice per group on the right. The survival data are presented as Kaplan-Meier 
plots (n = 5). Results from a Gehan-Breslow-Wilcoxon test revealed significant (p = 0.0036) 
differences between the survival curves of the different treatment groups. The body weight data is 
represented as mean body weight change  SD for each group. (black arrows: injections of the 







Figure 5. Analysis of tumor-infiltrating leukocytes (TIL) and tumor-draining lymph nodes (TDLN) 
(a) Composition of the tumor-infiltrating immune cells, including the CD8:CD4 ratio, the proportion 
of AH1-specific CD8+ T cells and regulatory CD4+ T cells in WEHI-164 and CT26 tumors treated 
with saline, F8-4-1BBL and the combo therapy (PD-1 and F8-4-1BBL). Proportion of AH1-
specific CD8+ T cells and regulatory CD4+ T cell are shown also for matching TDLNs. (b) 
Composition of the TDLNs in WEHI-164 and CT26 tumor-bearing mice, including the CD8:CD4 
ratio (c) Phenotype of the CD8+ T cells and AH1-specific CD8+ T cells in CD26 tumor-bearing 
mice from different treatment groups. The phenotype was assessed based on the expression of 
CD62L, CD44 and the exhaustion markers CD39 and PD-1. The data represents individual 
values, means and standard deviations.  Statistical evaluations were performed using a regular 
two-way ANOVA followed by a Tukey’s multiple comparison test using GraphPad Prism v8.4.1 [* 
p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001] (TIL: tumor-infiltrating leukocyte, NKT: natural 
killer T cell, NK: natural killer cell, APC: antigen-presenting cell, Treg: regulatory T cell, TDLN: 
tumor-draining lymph node, Teff: effector T cell [CD44+CD62L-], Tcm: central memory T cell 
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a: TILs in WEHI-164 fibrosarcoma and CT26 colon carcinoma

































































































































































































































































































































































































































































































































































































































b: composition of the tumor-draining lymph nodes (TDLN)
